Sony Salzman is a freelance journalist reporting on health care and medicine, who has won awards in both narrative writing and radio journalism. Follow Salzman on Twitter: @sonysalz.
Latest by Sony Salzman
Gilead Sciences is working with the federal government to roll out its pre-exposure prophylaxis (PrEP) donation program. Here, we detail what we know so far about how this will be implemented.
People in jail, who are often in the system for less time than those in prison, often receive little to no hepatitis C screening or treatment. One provider works to change this in Massachusetts.
The question of whether INSTIs cause weight gain continues to be debated. This story draws together some research on which drugs are associated with weight gain or other metabolic changes.
If everyone living with HIV gets into care, do we have enough providers to support them? HIV doctors are proposing policy changes to address the workforce shortage.
A series of studies aim to determine whether test-and-treat strategies can be implemented for people with hepatitis C, much like programs for people living with HIV.
The FDA approved the fixed-dose combination of emtricitabine and tenofovir alafenamide for PrEP, but advocates hope to see more research on the HIV prevention drug's efficacy for receptive vaginal sex for cisgender women and transgender men.
At IDWeek in Washington, D.C., leading infectious disease doctors and researchers met with U.S. Congress leadership to discuss HIV prevention, treatment, and care policy.
We're covering the latest news and research from this major interdisciplinary meeting on infectious diseases, which takes place in Washington, D.C., from Oct. 2 to Oct. 6.
But other research links prisons themselves to mental health challenges and infectious disease outbreaks.
"Genetics is less than half the story for sexual behavior, but it's still a contributing factor."